• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

    3/28/23 1:04:37 PM ET
    $ALLR
    $BABA
    $BDRX
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate
    Real Estate
    Get the next $ALLR alert in real time by email

    Gainers

    • Biomea Fusion, Inc. (NASDAQ:BMEA) surged 56.8% to $24.20 after the company announced data from the initial cohorts of the ongoing Phase II study of BMF-219 in patients with type 2 diabetes; 100mg cohort 3 demonstrated an 89% response rate and 1% median reduction in HbA1c at day 28.
    • Oscar Health, Inc. (NYSE:OSCR) shares jumped 54.9% to $5.54 after the company announced the appointment of healthcare veteran Mark Bertolini as CEO effective April 3, 2023.
    • Biodexa Pharmaceuticals (NASDAQ:BDRX) shares jumped 52% to $0.7150 after gaining 65% on Monday.
    • Viking Therapeutics, Inc. (NASDAQ:VKTX) gained 46.8% to $13.39 after the company reported results from its Phase 1 trial of VK2735 for the potential treatment of various metabolic disorders.
    • Beamr Imaging Ltd. (NASDAQ:BMR) rose 33.3% to $2.9745.
    • Mercurity Fintech Holding Inc. (NASDAQ:MFH) surged 26% to $1.7698.
    • Bird Global, Inc. (NASDAQ:BRDS) gained 24.4% to $0.17. Bird, on Monday, announced purchases of shares by management and directors.
    • ZW Data Action Technologies Inc. (NASDAQ:CNET) gained 23.5% to $2.15. ZW Data Action Technologies entered into cooperation agreement with Chaineffect (Guangzhou) Blockchain Technology.
    • Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) shares surged 20% to $57.48 after the company announced topline results from Study 403 evaluating lumateperone as monotherapy in patients with major depressive disorder with mixed features and bipolar depression with mixed features.
    • PVH Corp. (NYSE:PVH) rose 19% to $87.57 after the company posted better-than-expected results for its fourth quarter and issued strong FY23 earnings forecast.
    • Guardion Health Sciences, Inc. (NASDAQ:GHSI) climbed 18.3% to $7.38.
    • Milestone Pharmaceuticals Inc. (NASDAQ:MIST) gained 15.3% to $4.1506. Milestone Pharmaceuticals announced a $125 million strategic funding with an existing shareholder.
    • The Lovesac Company (NASDAQ:LOVE) rose 14.7% to $27.52 after the company announced better-than-expected Q4 EPS and sales results and issued FY24 EPS and sales guidance above estimates.
    • Silvergate Capital Corporation (NYSE:SI) shares rose 13.7% to $2.24. Silvergate Capital shares gained around 15% on Monday after MacroStrategy reported it voluntarily prepaid its Silvergate Bank loan. MicroStrategy prepaid approximately $161.0 million.
    • McCormick & Company, Incorporated (NYSE:MKC) gained 12.2% to $83.14. McCormick & Co reported first-quarter FY23 sales growth of 3% year-on-year to $1.57 billion, beating the consensus of $1.54 billion.
    • Purple Innovation, Inc. (NASDAQ:PRPL) surged 11.8% to $2.8085.
    • IHS Holding Limited (NYSE:IHS) jumped 11.6% to $7.92 following Q4 results.
    • Standard Lithium Ltd. (NYSE:SLI) gained 10.9% to $3.6385.
    • Cidara Therapeutics, Inc. (NASDAQ:CDTX) shares rose 9.9% to $1.11. Cidara Therapeutics President and CEO Jeffrey Stein acquired a total 50,000 shares at an average price of $1.04.
    • Alibaba Group Holding Limited (NYSE:BABA) gained 8.3% to $93.31 following a report suggesting the company will be splitting into six units that may pursue individual IPOs.
    • Proterra Inc. (NASDAQ:PTRA) gained 8.3% to $1.57.

    Losers

    • Monopar Therapeutics Inc. (NASDAQ:MNPR) shares declined 49.8% to $1.4890 after the company announced it will be discontinuing its Validive Phase 2b/3 VOICE trial along with the active development of Validive after the company was informed the trial didn't meet the pre-defined threshold for efficacy.
    • Virgin Orbit Holdings, Inc. (NASDAQ:VORB) shares dropped 27% to $ 0.39. Virgin Orbit is extending its pause in operation to pursue investment, CNBC reported, citing a company-wide mail by CEO Dan Hart.
    • Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) fell 26.4% to $30.53 after Scorpion Capital issued a short report on the company.
    • WiSA Technologies, Inc. (NASDAQ:WISA) fell 25.7% to $2.67 after jumping around 89% on Monday.
    • OncoSec Medical Incorporated (NASDAQ:ONCS) shares fell 20.5% to $2.10.
    • TRxADE HEALTH, Inc. (NASDAQ:MEDS) dropped 20.3% to $0.3625 following a wider-than-expected quarterly loss.
    • Draganfly Inc. (NASDAQ:DPRO) fell 18.2% to $1.43 after posting a loss for the fourth quarter.
    • Better Choice Company Inc. (NYSE:BTTR) dropped 16.6% to $0.3701 following weak quarterly sales.
    • Boxed, Inc. (NYSE:BOXD) declined 14.3% to $0.1740.
    • Allarity Therapeutics, Inc. (NASDAQ:ALLR) dropped 12.8% to $2.2399. Allarity Therapeutics said that for Ixempra and stenoparib monotherapy trials, Allarity is taking steps to accelerate patient recruitment to support the goals for interim data readouts by the end of 2023.
    • Finch Therapeutics Group, Inc. (NASDAQ:FNCH) fell 12.5% to $0.35. Finch Therapeutics Group recently posted a Q4 loss of $0.56 per share.
    • iHeartMedia, Inc. (NASDAQ:IHRT) dipped 11.6% to $3.79. B of A Securities downgraded iHeartMedia from Neutral to Underperform and lowered the price target from $6.5 to $4.
    • Puyi Inc. (NASDAQ:PUYI) fell 11.2% to $5.77.
    • CytomX Therapeutics, Inc. (NASDAQ:CTMX) fell 10.1% to $1.61 after the company posted results for its fourth quarter.
    • BM Technologies, Inc. (NASDAQ:BMTX) dropped 9.6% to $3.48 following weak quarterly sales.
    • Invesco Mortgage Capital Inc. (NYSE:IVR) fell 5% to $10.64 after the company announced a cash dividend of $0.40 per share of common stock for the first quarter and issued an update on estimated results of operations, portfolio, liquidity and book value.

    Now Read This: Bitcoin Falls Below $27,000; Mina, Arbitrum Among Top Losers

    Get the next $ALLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLR
    $BABA
    $BDRX
    $BMEA

    CompanyDatePrice TargetRatingAnalyst
    Oscar Health Inc.
    $OSCR
    4/20/2026$16.00Underperform → Hold
    Jefferies
    McCormick & Company Incorporated
    $MKC
    4/14/2026Neutral
    BTIG Research
    Milestone Pharmaceuticals Inc.
    $MIST
    4/10/2026$6.00Strong Buy
    Raymond James
    Viking Therapeutics Inc.
    $VKTX
    3/26/2026Peer Perform
    Wolfe Research
    Draganfly Inc.
    $DPRO
    3/25/2026$14.00 → $12.00Buy
    Needham
    PVH Corp.
    $PVH
    3/24/2026$82.00 → $74.00Market Perform
    Telsey Advisory Group
    Alibaba Group Holding Limited
    $BABA
    3/20/2026$135.00Buy → Hold
    DZ Bank
    CytomX Therapeutics Inc.
    $CTMX
    3/16/2026$12.00Neutral → Overweight
    Analyst
    More analyst ratings

    $ALLR
    $BABA
    $BDRX
    $BMEA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Human Relations Officer Piper Sarah

    4 - MCCORMICK & CO INC (0000063754) (Issuer)

    4/23/26 3:37:17 PM ET
    $MKC
    Packaged Foods
    Consumer Staples

    SEC Form 4 filed by Chairman, President & CEO Foley Brendan M

    4 - MCCORMICK & CO INC (0000063754) (Issuer)

    4/23/26 3:35:52 PM ET
    $MKC
    Packaged Foods
    Consumer Staples

    SEC Form 4 filed by Ahearn Matthew Fraser

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    4/21/26 4:39:18 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $ALLR
    $BABA
    $BDRX
    $BMEA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oscar Health upgraded by Jefferies with a new price target

    Jefferies upgraded Oscar Health from Underperform to Hold and set a new price target of $16.00

    4/20/26 8:21:17 AM ET
    $OSCR
    Medical Specialities
    Health Care

    BTIG Research initiated coverage on McCormick

    BTIG Research initiated coverage of McCormick with a rating of Neutral

    4/14/26 8:24:09 AM ET
    $MKC
    Packaged Foods
    Consumer Staples

    Raymond James initiated coverage on Milestone Pharmaceuticals with a new price target

    Raymond James initiated coverage of Milestone Pharmaceuticals with a rating of Strong Buy and set a new price target of $6.00

    4/10/26 8:32:45 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BABA
    $BDRX
    $BMEA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 7, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-274-8461 (domestic) or 203-518-9814 (international or alternate), and reference passcode HRMYQ126. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Bioscien

    4/23/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

    Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi

    4/23/26 6:15:00 AM ET
    $LGVN
    $LLY
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026

    Conference Call Scheduled for Wednesday, April 29 at 4:30 p.m. Eastern Time SAN DIEGO, April 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter of 2026 after the market close on Wednesday, April 29, 2026. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on We

    4/22/26 4:35:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BABA
    $BDRX
    $BMEA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Points Jeffrey S. exercised 13,264 shares at a strike of $2.48 and bought $30,000 worth of shares (2,000 units at $15.00), increasing direct ownership by 27% to 70,785 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/17/26 5:42:34 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Director Buchholz Richard bought $14,840 worth of shares (1,000 units at $14.84), increasing direct ownership by 8% to 13,666 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/17/26 5:34:29 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    CEO & Executive Chairman Ball Robert Joseph bought $33,392 worth of shares (2,200 units at $15.18), increasing direct ownership by 0.80% to 278,866 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/17/26 5:31:09 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $ALLR
    $BABA
    $BDRX
    $BMEA
    SEC Filings

    View All

    Amendment: SEC Form S-3/A filed by Allarity Therapeutics Inc.

    S-3/A - Allarity Therapeutics, Inc. (0001860657) (Filer)

    4/24/26 1:01:50 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by The Lovesac Company

    DEFA14A - Lovesac Co (0001701758) (Filer)

    4/23/26 7:16:17 AM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    SEC Form DEF 14A filed by The Lovesac Company

    DEF 14A - Lovesac Co (0001701758) (Filer)

    4/23/26 7:15:37 AM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    $ALLR
    $BABA
    $BDRX
    $BMEA
    Financials

    Live finance-specific insights

    View All

    Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 7, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-274-8461 (domestic) or 203-518-9814 (international or alternate), and reference passcode HRMYQ126. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Bioscien

    4/23/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

    Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi

    4/23/26 6:15:00 AM ET
    $LGVN
    $LLY
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026

    Conference Call Scheduled for Wednesday, April 29 at 4:30 p.m. Eastern Time SAN DIEGO, April 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter of 2026 after the market close on Wednesday, April 29, 2026. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on We

    4/22/26 4:35:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BABA
    $BDRX
    $BMEA
    Leadership Updates

    Live Leadership Updates

    View All

    Oscar Health, Inc. Appoints Director Siddhartha Sankaran as Independent Chair of the Board

    Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, today announced the appointment of independent director Siddhartha Sankaran as Chair of the Board, effective June 4, 2026. Sankaran will succeed Jeffery Boyd, who has served as Chair since February 2021 and is not standing for reelection at Oscar Health's Annual Meeting. Sankaran has more than 20 years of leadership in the insurance industry, serving in executive roles at multiple public companies, including at American International Group, Inc., SiriusPoint Ltd. and FWD Group Holdings Limited. He brings a wealth of expertise from serving on numerous boards. He also contributed to building

    4/21/26 6:30:00 AM ET
    $OSCR
    Medical Specialities
    Health Care

    Oklo Announces Changes to its Board of Directors and Management Team to Support its Continued Growth

    Oklo welcomes Dr. Mark Peters, David Christian, Derek Kan, and David Park as new directors, bringing decades of experience executing complex and highly technical projects across a range of industries Oklo appoints Michael Thompson as Lead Independent Director Oklo announces plan to transition Pat Schweiger from Chief Technology Officer to a senior technical advisor Oklo Inc. (NYSE:OKLO), an advanced nuclear technology company, today announced changes to its Board of Directors and management team designed to enable Oklo to meet its ambitious deployment goals across its integrated power-fuel-isotopes business. "Over the past two years, we have built distinct business units respons

    4/14/26 4:15:00 PM ET
    $GL
    $OKLO
    $SLI
    Life Insurance
    Finance
    Electric Utilities: Central
    Utilities

    Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer

    COMPANY REITERATES ITS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION IN WAKIX SALES Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced the appointment of Glenn Reicin as Chief Financial Officer, effective immediately, supporting Harmony's continued focus on strategic growth, financial strength, and long‑term value creation. Harmony is also reiterating its 2026 net product revenue guidance of $1.0 to $1.04 billion. Mr. Reicin is a seasoned biopharmaceutical executive with extensive experience across publicly traded and privately held companies, guiding them through key growth inflection points. With his experience as a sell-side analyst, investor and biotech CFO, he brings

    4/14/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BABA
    $BDRX
    $BMEA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

    SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

    12/17/24 5:01:42 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/9/24 5:37:15 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/4/24 4:15:14 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $BABA
    $BDRX
    $BMEA
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

    Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

    6/22/24 8:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care